GAGNO, SARA
 Distribuzione geografica
Continente #
NA - Nord America 700
AS - Asia 195
EU - Europa 128
AF - Africa 2
SA - Sud America 1
Totale 1.026
Nazione #
US - Stati Uniti d'America 698
CN - Cina 96
SG - Singapore 75
IT - Italia 56
DE - Germania 16
FI - Finlandia 15
FR - Francia 13
IE - Irlanda 6
IN - India 6
GB - Regno Unito 4
BE - Belgio 3
IQ - Iraq 3
JP - Giappone 3
LT - Lituania 3
SE - Svezia 3
TR - Turchia 3
VN - Vietnam 3
CA - Canada 2
EG - Egitto 2
HK - Hong Kong 2
NL - Olanda 2
RU - Federazione Russa 2
UA - Ucraina 2
UZ - Uzbekistan 2
BR - Brasile 1
CZ - Repubblica Ceca 1
ID - Indonesia 1
KR - Corea 1
PL - Polonia 1
RO - Romania 1
Totale 1.026
Città #
Chandler 101
Fairfield 84
Singapore 69
Ashburn 51
Ann Arbor 42
Cambridge 39
Santa Clara 37
Houston 33
Seattle 33
Woodbridge 30
Beijing 29
Boardman 29
Wilmington 27
San Diego 19
Des Moines 15
Padova 15
Medford 14
Princeton 14
New York 12
Helsinki 11
Cagliari 6
Trieste 6
Guangzhou 4
Nanjing 4
Ankara 3
Changsha 3
Najaf 3
Pordenone 3
Shenyang 3
Venezia 3
Belluno 2
Cairo 2
Dublin 2
Fort Worth 2
Haikou 2
Hebei 2
Hefei 2
Hong Kong 2
Jinan 2
Kharkiv 2
Roxbury 2
Sacile 2
Tashkent 2
Toronto 2
Waanrode 2
Bengaluru 1
Brussels 1
Carapelle 1
Chengdu 1
Chiampo 1
Chicago 1
Chiswick 1
Dalian 1
Dallas 1
Dezhou 1
Frankfurt am Main 1
Gdansk 1
Hangzhou 1
Hanoi 1
Hyderabad 1
Jakarta 1
Jianning 1
Kunming 1
Lappeenranta 1
Lastra A Signa 1
London 1
Los Angeles 1
Mangalore 1
Montegrotto Terme 1
Moscow 1
Naples 1
Ningbo 1
Norwalk 1
Ocala 1
Osaka 1
Prescot 1
Redmond 1
Rio Verde 1
Sendai 1
Shanghai 1
Taizhou 1
Tappahannock 1
Tokyo 1
Washington 1
Wenzhou 1
Wuhan 1
Zhoukou 1
Totale 814
Nome #
Pharmacogenetics biomarkers and their specific role in neoadjuvant chemoradiotherapy treatments: An exploratory study on rectal cancer patients 129
Impact of DNA repair gene polymorphisms on the risk of biochemical recurrence after radiotherapy and overall survival in prostate cancer 90
A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer 85
A new high-performance liquid chromatography–tandem mass spectrometry method for the determination of sunitinib and N-desethyl sunitinib in human plasma: Light-induced isomerism overtaking towards therapeutic drug monitoring in clinical routine 75
Innovative strategies for tailoring therapy in cancer patient: pharmacogenetics and hormone therapy personalization in metastatic or locally advanced breast cancer patients treated with Exemestane 73
Immunogenetic markers in IL17F predict the risk of metastases spread and overall survival in rectal cancer patients treated with neoadjuvant chemoradiotherapy 64
Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines 61
Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients 57
A LC–MS/MS method for therapeutic drug monitoring of sorafenib, regorafenib and their active metabolites in patients with hepatocellular carcinoma 55
Il15ra and smad3 genetic variants predict overall survival in metastatic colorectal cancer patients treated with folfiri therapy: A new paradigm 51
A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer 46
Therapeutic drug monitoring of palbociclib, ribociclib and letrozole in women with breast cancer by LC-MS 44
A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring 41
Dried Blood Spot Technique Applied in Therapeutic Drug Monitoring of Anticancer Drugs: a Review on Conversion Methods to Correlate Plasma and Dried Blood Spot Concentrations 36
A new LC-MS/MS method for the simultaneous quantification of abemaciclib, its main active metabolites M2 and M20, and letrozole for therapeutic drug monitoring 22
LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring 16
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer 16
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer 15
Bioanalytical Methods for Poly(ADP-Ribose) Polymerase Inhibitor Quantification: A Review for Therapeutic Drug Monitoring 12
The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure 11
A fast and validated LC-MS/MS method to quantify lenvatinib in dried blood spot 11
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure 10
Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis 9
Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method 8
Increased plasma imatinib exposure and toxicity in chronically treated GIST patients with SARS-CoV-2 infection: a case series 7
Exploring pharmacokinetic variability of palbociclib in HR+/HER2- metastatic breast cancer: a focus on age, renal function, and drug-gene interactions 7
Quantification of Letrozole, Palbociclib, Ribociclib, Abemaciclib, and Metabolites in Volumetric Dried Blood Spots: Development and Validation of an LC-MS/MS Method for Therapeutic Drug Monitoring 4
Totale 1.055
Categoria #
all - tutte 5.828
article - articoli 5.500
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.328


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020105 0 0 0 0 0 8 14 21 18 20 17 7
2020/2021109 8 6 7 13 7 6 1 20 17 11 9 4
2021/2022205 14 32 11 13 4 20 12 18 8 19 14 40
2022/2023190 25 32 4 25 27 25 2 10 18 4 13 5
2023/2024115 4 11 8 11 7 27 11 13 3 5 6 9
2024/2025269 7 78 31 42 68 43 0 0 0 0 0 0
Totale 1.055